The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

Things are, however, looking good for its latest launch, respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales. Zealand Pharma has suffered ...

Eliminating fake vaccine news with pharmacist, nurse, and physician review. According to the Pan American Health Organization (PAHO) chikungunya data dashboard, the Federative Republic of Brazil has ...